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Abstract: Atherogenesis starts from the fetal life, and its natural course consists of interrelations between traditional risk 
factors and inflammatory, immune, and endothelial biomarkers. Even the early-stages of atherosclerotic lesions, i.e. fatty 
streaks present the features of chronic inflammation. Markers of inflammation are associated with insulin resistance and 
major  atherosclerosis risk factors. Several studies have  confirmed a relationship between surrogate markers of future  
cardiovascular disease with childhood obesity, notably abdominal obesity, as well as with the degree of obesity. Moreo-
ver, functional and structural changes are documented in arteries of children with a familial predisposition to atheroscle-
rotic diseases; these changes are associated with clusters of inflammatory factors and markers of oxidation. In addition to 
the  development  of  atheromatous  plaques,  inflammation  also  plays  an  essential  role  in  the  destabilization  of  artery 
plaques, and in turn in the occurrence of acute thrombo-embolic disorders. Markers of inflammation can provide predic-
tive clinical information about outcomes of patients with acute coronary syndromes, independent of the extent of myocar-
dial  damage.  Moreover,  serum  levels  of  the  inflammatory  markers  might  add  prognostic  information  provided  by  
traditional risk factors. Platelets have an important role in vascular inflammation and atherosclerosis and in the formation 
of mural thrombi. As lifestyle modification trials have been successful in decreasing endothelial dysfunction and the level 
of markers of inflammation among children and adolescents, it is suggested that in addition to expanding pharmacological 
therapies considered for secondary prevention of atherosclerotic diseases aiming to control the inflammatory process, the 
importance of primordial/primary prevention of atherosclerosis should be underscored. 
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INTRODUCTION 
  Atherogenesis is the developmental process of atheroma-
tous  plaques  characterized  by  a  remodeling  of  arteries i n-
volving the concomitant accumulation of plaques. During the 
past  decades,  numerous  theories  or  hypotheses  have  been 
proposed about atherogenesis that was previously considered 
a cholesterol storage disease. Although none of theories or 
hypotheses could entirely explain the whole process of the 
pathogenesis of atherosclerosis, but there is a growing body 
of evidence about the role of inflammation in this process. It 
is suggested that atherosclerosis is a specific form of chronic 
inflammatory  process  resulting  from  interactions  between 
plasma  lipoproteins,  cellular  components  as  monocyte/ 
macrophages, T lymphocytes, endothelial cells and smooth 
muscle cells as well as the extracellular matrix of the arteries 
[1-3]. 
  The major risk factors of atherosclerosis induce the se-
cretion of leukocyte soluble
 adhesion molecules, which fa-
cilitate the attachment of monocytes
 to endothelial cells, and 
chemotactic factors, which in turn promote
 the monocytes’  
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movement into the subintimal space. It is suggested that the
 
transformation  of  monocytes  into  macrophages  and  the  
uptake
 of cholesterol lipoproteins initiate the production of 
fatty
  streaks.  Additional  damaging  stimuli  would  maintain 
the accumulation of macrophages, mast cells, and activated 
T
 cells in the growing atherosclerotic lesions [4, 5]. 
  Inflammatory cytokines related to vascular inflammation 
stimulate the production of endothelial adhesion molecules, 
proteases, and other soluble mediators. They also induce the 
generation of the messenger cytokine interleukin-6, which in 
turn  stimulates  the  liver  to  increase  production  of  acute-
phase reactants such as C-reactive protein (CRP). In addi-
tion, platelets and adipose tissue can generate inflammatory 
mediators relevant to atherogenesis and thrombosis [6].  
INFLAMMATORY PROCESS OF ATHEROGENESIS 
FROM FETAL LIFE 
  The first stages of atherogenesis begin from the fetal life. 
A local inflammatory process is suggested to contribute in 
reestablishment  of  the  homeostasis  of  the  vascular  wall 
through  promoting  the  removal  of  injured  tissue  and  its  
consequent  repair.  The  endothelial  permeability  of  some 
arterial  segments  alters  and  allows  the  infiltration  of  
macromolecules,  like lipoproteins, in the subintimal space. 
Oxidized lipoproteins induce the expression of chemokines 
and  adhesion  molecules  on  the  luminal  surface  of  the  
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endothelium,  which  allow  the  local  recruitment  of  
monocytes-macrophages and T lymphocytes [7]. 
  Even the early-stages of atherosclerotic lesions, i.e. fatty 
streaks present the features of chronic inflammation. Athero-
genic lipoproteins such as oxidized low density lipoprotein 
(ox- LDL), remnant lipoprotein and lipoprotein (a) have  a 
significant  role  in  the  pro-inflammatory  reaction,  whereas 
high  density  lipoprotein  (HDL),  anti-atherogenic  lipopro-
teins, have anti-inflammatory function [2, 5-7].  
  Changes  in  the  proteoglycan  metabolism  of  the  intima 
are associated to the early stages of atherosclerosis. Matrix 
metalloproteinases  (MMPs)  are  a  group  of  zinc-dependent 
proteases produced by a variety of cell types, including en-
dothelial, smooth muscle cells and monocytes. MMPs exist 
at low levels in normal adult tissue, and are synchronized in 
physiological and pathological remodeling processes. They 
are specialized enzymes involved in various stages of vascu-
lar  diseases.  The  imbalance  of  matrix  metalloproteinases 
(MMPs) and their inhibiting factors, i.e. tissue inhibitors of 
metalloproteinases  (TIMPs)  has  a  crucial  role  in  early 
changes of atherosclerosis and its progression [8]. Experi-
mental studies have shown that MMPs derived from arterial 
cells
  are required for early  atherosclerotic plaque develop-
ment
 and cellular accumulation [9, 10]. MMPs are consid-
ered  to  mediate  the  progression  of  stable  atherosclerotic  
lesions to an unstable plaque prone to rupture [11]. 
  Angiotensin  II  is  a  proinflammatory  mediator  that  
induces the development and progression of atherosclerosis; 
it  provokes  pro-atherosclerotic  cytokine  and  chemokine  
secretion and increases endothelial dysfunction. Angiotensin 
promotes macrophage migration into the vascular intima and 
elastin breaks, it is essential in beginning the atherosclerosis 
process  [12].  Accordingly,  the  medications  inhibiting  the 
rennin-angiotensin  system  are  being  used  both  primary  
and  secondary  prevention  of  atherosclerotic  cardiovascular 
disease [13]. 
INFLAMMATORY BIOMARKERS AS PREDICTORS 
OF FUTURE ATHEROSCLEROSIS 
  The  association  of  inflammatory  processes  with  the  
development  of  atherosclerosis  provides  important  links  
between  underlying  mechanisms  of  atherogenesis  and  risk 
factors.  Therefore,  more  interest  has  focused  on  studies 
about  inflammatory  biomarkers  as  predictors  of  future  
clinical  events.  Several  studies  have  examined  different  
circulating markers of inflammations, such as cytokines and 
adhesion  molecules,  as  potential  predictors  of  the  present 
and the future risk of cardiovascular diseases , most studies 
have  determined  the  following  factors:  ox-LDL,  pro-
inflammatory cytokines as interleukin-1 and tumor necrosis 
factor- ,  adhesion  molecules  as  intercellular
  adhesion  
molecule-1 and selectins, inflammatory stimuli with hepatic
 
effects as interleukin-6 or the products of the hepatic stimu-
lation,
 such as serum amyloid
 A (SAA), high-sensitivity CRP 
(  hs  CRP)  and  a  host  of  other  acute-phase
  reactants  and  
leukocyte  count.  Furthermore,  soluble  CD40  ligand,  
adiponectin, interleukin 18, and matrix metalloproteinase 9 
are  considered  to  provide  additional  information  for 
cardiovascular risk stratification and prediction [6]. Elevated 
plasma levels of molecules such as soluble intercellular ad-
hesion  molecule-1,  interleukin-6  and  hs  CRP  have  been 
found  to  represent  inflammatory  markers  of  future  risk  of 
atherosclerotic  diseases.  Among  these  factors,  CRP  has 
emerged  as  the  most  influential  and  available  marker  for 
clinical and epidemiological use. 
  An  association  between  this  sensitive  marker  of  
inflammation and the development of atherosclerotic disease  
has been documented in different experimental [14-17] and 
epidemiological  studies  [18-21].  Some  epidemiological  
studies  have  confirmed  that  high-sensitivity  CRP  (hsCRP) 
might predict future atherosclerotic diseases among healthy 
individuals.  Moreover,  platelets  and  adipose  tissue  might 
produce inflammatory mediators related to atherothrombosis.  
  It is suggested that cholesterol itself may generate a pro-
inflammatory process resulting in atherosclerosis [22]. When 
trapped in the
 intima, oxidized products of
 LDL-C might be 
active  as  pro-inflammatory  mediators.  Human  and  animal 
studies  have  suggested  a  strong
  correlation  between  the  
auto-antibodies  against
  oxidized  LDL  and  the  extent  of  
atherosclerosis [23]. Cholesterol synthesis is associated with 
interleukin-6  mediated  inflammation,  which  in  turn  is  the 
common causative factor for aging and age-related disorders 
including atherosclerosis [24, 25]. 
INFLAMMATORY  BIOMARKERS  AND  INSULIN 
RESISTANCE  
  It  is  well  documented  that  markers  of  the  acute-phase 
response,  including  CRP  are  associated  with  insulin  resis-
tance  [21-29],  body  mass  index  (BMI)  [21,  26,  27,  29],  
serum glucose [26] and lipids [21, 26, 27, 29]. 
  Serum  hs  CRP  and  interleukin-6  are  independent  risk 
factors for atherosclerosis in obese,  insulin-resistant  adults 
[30, 31]. However, some studies have documented the asso-
ciation of CRP with cardiovascular disease, independent to 
insulin  resistance  [18-21].  Such  studies  have  implicated  
inflammation as an essential contributor to the progression of 
atherosclerosis.  Elevated  serum  levels  of  inflammatory 
markers, including CRP, are documented in type 2 diabetic 
patients  with  components  of  insulin  resistance.  It  is  
suggested that insulin insensitivity and/or hyperinsulinemia 
may be associated with serum CRP levels [28].  
  CRP level is also related to the risk for future cardiovas-
cular morbidity and mortality among those with documented 
vascular disease as well as apparently healthy individuals. It 
is noteworthy to mention that in some studies, the risk pre-
diction of hs-CRP has been independent of traditional risk 
factors [18].  Longitudinal studies documented  a predictive 
role of elevated circulating levels of soluble (s) intercellular 
cell  adhesion  molecule-1  (ICAM-1)  in  healthy  people,  of 
vascular cell adhesion molecule-1(sVCAM-1) in patients at 
high risk or with documented cardiovascular diseases [32-
34]. 
  Generally, it is documented  that all  the  conditions  that 
increase circulating fatty acids and cause lipid overloading 
induce  a lipotoxic state  in non-adipose  tissues  that predis-
pose insulin resistance and subsequent disorders [35]. 26    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Roya Kelishadi 
ASSOCIATION  OF  ENDOTHELIAL  DYSFUNCTION 
AND INFLAMMATION FROM EARLY LIFE 
  Atherogenesis starts from early life, and its natural course 
is an area under discussion of interrelations between tradi-
tional risk factors and inflammatory, immune, and endothe-
lial biomarkers. Excessive production of CRP and other in-
flammatory  biomarkers  may  accelerate  atherogenesis  in 
children and lead to long-term atherothrombotic events [36]. 
As  endothelial  dysfunction  and  atherosclerosis  begin  from 
early life, studying the association of their early stages with 
markers of inflammation would give a better insight of this 
process, independent of the process of aging. A study that 
determined the association of hs CRP with vascular endothe-
lial and smooth muscle dysfunction in children with type 1 
diabetes mellitus and healthy controls, hsCRP was not asso-
ciated with early vascular dysfunction in normal-weight dia-
betic children, but such association was documented in those 
with higher BMI [37]. Another study investigated the rela-
tionship of hs CRP with BMI and cardiovascular risk factors 
in obese children and adolescents. It found that hs CRP level 
was correlated with BMI, systolic and diastolic blood pres-
sure and serum  leptin  levels. It  confirmed the relationship 
between obesity, inflammation and atherosclerosis, and sug-
gested that hs CRP in childhood obesity might be a useful 
index to predict possible atherosclerotic events [38]. 
  Studies on the relationship between the degree of child-
hood obesity and surrogate markers of future cardiovascular 
disease revealed that CRP and interleukin-6 levels increased 
with  the  degree  of  obesity.  This  finding  suggests  that  the 
degree of low-grade inflammation may increase as children 
become more obese. However, C-reactive protein levels did 
not correlate significantly with insulin resistance or with the 
metabolic syndrome, suggesting that an underlying inflam-
mation may be an additional factor contributing to adverse 
long-term cardiovascular outcomes [39]. 
  Endothelial  adhesion  molecules,  including  endothelial-
leukocyte  adhesion  molecule  (E-selectin),  ICAM-1,  and 
VCAM-1 have a crucial role in the earliest stages of athero-
genesis by mediating the binding and recruitment of mono-
cytes into arterial intima [40].Concentrations of hs CRP and 
soluble adhesion molecules are higher in obese than in other 
children  [41,42].  A  population-based  study  among  healthy 
children and adolescents found a significant correlation be-
tween CRP and markers of oxidative stress, as well as be-
tween CRP and these markers with abdominal obesity, but 
not with generalized obesity [43]. 
  Childhood obesity  and associated  cardio-metabolic risk 
factors are no more limited to industrialized countries, but 
also a growing problem in low- and middle-income countries 
[44]. Therefore, future atherosclerotic diseases in young age 
would become a major health threat worldwide. Modifiable 
lifestyle behaviors are associated with childhood obesity [45] 
and cardio-metabolic risk factors [46]. Given that short-term 
lifestyle modification programs have been successful in im-
provement of lipid profile, markers of inflammation and en-
dothelial  dysfunction  among  obese  youths  [47,  48],  early 
recognition and control of risk factors and in turn inflamma-
tion might have long-term impact on prevention and control 
of  atherosclerosis  and  underlying  inflammatory  processes. 
Cardio-metabolic risk factors are not limited to obese indi-
viduals, and are documented in some normal weight children 
and adolescents, termed phenotypically normal metabolically 
obese youths [49].  
  In addition to the lipids and apolipoproteins, the markers 
of inflammation and oxidative stress as well as the carotid- 
intima  media  thickness  of  normal-weight  children  with  a 
metabolic abnormality are found to be similar to obese chil-
dren.  Furthermore,  irrespective  of  obesity  and  metabolic 
abnormality,  fitness  is  shown  to  have  the  highest  inverse 
correlation  with  markers  of  insulin  resistance  and  non-
alcoholic fatty liver diseases among adolescents [50]. 
  Lifestyle modification trial has been successful in reduc-
ing serum CRP level among both normal-weight and obese 
children and adolescents with cardio-metabolic risk factors 
[51]. 
  Given that cardio-metabolic risk factors track from early 
life to adulthood, and that childhood CRP value predict adult 
CRP, and this association is found to be independent of other 
metabolic risk factors such as serum lipids, blood pressure, 
smoking,  obesity  indices,  and  insulin  [52],  and  that  high 
CRP  is  one  of  the  youth  determinants  of  adult  metabolic 
syndrome  [53],  all  children  and  adolescents,  and  not  only 
those with overweight, should be encouraged to have health-
ier lifestyle that would help the primordial/primary preven-
tion of atherosclerotic diseases. 
INFLAMMATORY  CHANGES  AND  PRECURSORS 
OF  ATHEROSCLEROSIS  IN  CHILDREN  WITH 
POSITIVE  FAMILY  HISTORY  OF  PREMATURE 
CORONARY HEART DISEASE 
  Offspring of patients with premature atherosclerotic dis-
ease may be at increased risk for atherosclerosis. Screening 
and  control  of  atherosclerosis’  risk  factors  are  of  special 
concern for these children who are at high-risk for premature 
atherosclerotic cardiovascular diseases. In addition to higher 
levels of lipids and lipoproteins [54], markers of oxidation 
[55], hs CRP [56] and immunologic factors [57], structural 
and functional changes in arteries are present at an early age 
in the arteries of individuals with a parental history of pre-
mature atherosclerosis [56, 58]. It is documented that the 19-
year-old  offspring  of  patients  with  premature  myocardial 
infarction had lower flow-mediated reactivity of the brachial 
arteries  and  greater  mean  intima-media  thickness  of  the 
common carotid artery. In those individuals with a parental 
history of premature myocardial infarction, an inverse asso-
ciation  was  found  between  brachial-artery  reactivity  and 
carotid intima-media thickness. This study also documented 
that both brachial-artery reactivity and carotid intima-media 
thickness  were  significantly  and  independently  correlated 
with  a parental history of premature myocardial infarction 
[58]. Vascular structural changes, as increased intima media 
thickness of the carotid artery, are detectable in children and 
adolescents,  and  might  occur  independently  of  traditional 
cardiovascular  risk  factors  [59].  It  is  documented  that  in 
children and adolescents with parental history of premature 
coronary heart diseases, clusters of inflammatory factors and 
markers of oxidation as well as carotid-intima media thick-
ness  and  left  ventricular  mass  were  correlated  with  each 
other and are associated with a positive parental history of 
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findings complement  the functional  and structural  changes 
documented in arteries of adults with a familial predisposi-
tion to atherosclerotic diseases. 
  CRP is one of the best markers for prediction of incident 
coronary artery diseases; this association is shown to be in-
dependent  of  other  established  risk  factors  [62].  CRP  and 
oxidation are correlated; oxidative stress may be a determi-
nant of CRP levels and promote the pro-atherosclerotic in-
flammatory process [63], and CRP can weakens the antioxi-
dant
 defenses of endothelial progenitor cells and might pre-
dict future vascular events [64]. The relation of inflamma-
tory  factors  and  family  history  of  coronary  heart  diseases 
among  children  and  adolescents  is  a  confirmatory  finding 
that subclinical chronic inflammation may have a major role 
in the development of atherosclerosis. These findings under-
score  the  importance  of  using  a  high-risk  approach  for  
primordial/primary  prevention  of  atherosclerotic  diseases 
from early life. 
INFLAMMATION AND THROMBOEMBOLISM 
  Inflammation is not only instrumental in the development 
of atheromatous plaques, but also plays an essential role in 
the  destabilization  of  artery  plaques,  and  in  turn  altering 
chronic atherosclerosis into an acute thrombo-embolic disor-
der. A number of humoral factors including cytokines, cy-
clooxygenase-2, matrix metalloproteinases, and tissue factor 
are involved in the process of plaque destabilization [65]. 
  A growing body of evidence indicate that the association 
of inflammation with atherosclerosis can provide predictive 
clinical information. Elevation in markers of  inflammation 
predicts  outcomes  of  patients  with  acute  coronary  syn-
dromes,  independent  of  the  extent  of  myocardial  damage. 
Moreover, serum levels of the inflammatory markers as CRP 
might  add  prognostic  information  provided  by  traditional 
risk factors [66, 67].
 
  As proposed by Libby and Theroux, “the findings on the 
widespread nature of inflammation in patients prone to de-
velop ACS challenge the traditional view of coronary athero-
sclerosis as a segmental or localized disease. Thus, treatment 
of acute coronary syndromes should involve two overlapping 
phases: first, addressing the culprit lesion, and second, aim-
ing at rapid stabilization of other plaques that may produce 
recurrent events” [1] 
  Platelets have an important role in vascular inflammation 
and atherosclerosis. They exert essential role in modulating 
inflammatory and immune processes. During the early stages 
of atherosclerosis, platelets adhere to endothelial cells, and in 
later  stages  they  participate  in  the  formation  of  mural 
thrombi [68]. They can stimulate the secretion of chemoki-
nes
 in cells of the vascular wall cells [69]; some chemokines 
accelerate  platelet
  aggregation  and  adhesion  [70],  in  turn 
activated platelets release
 chemokines and precursors
 which 
trigger atherogenesis or modulate
 key processes such as an-
giogenesis  and  lipoprotein  metabolism  [71].  Platelet  adhe-
sion  depends  on  the  interaction  of  subendothelial  matrix 
components,  such  as  collagen,  fibronectin  and  von  Wille-
brand factor with other adhesive proteins platelet receptors. 
Platelet adhesion activates the platelet release of inflamma-
tory substances that will result to firm platelet aggregation 
and thrombus formation [72]. As supposed by Weber, “An 
intricate  functional  relationship  between  platelets  and 
chemokines
  emerges  from  the  multiple  interactions.  The 
mechanisms provide  a framework
 for synergistic functions 
and allow  insights into the deleterious
 basis for proathero-
genic, proinflammatory, or thrombogenic effects
 exerted by 
two  prime  suspects  in  the  pathogenesis  of  vascular
  dis-
ease.”[73]. Thus, pharmacological  therapies  considered for 
secondary prevention of atherosclerotic diseases aim to con-
trol the inflammatory process [74], and they need to be ex-
panded. 
CONCLUSIONS 
  Atherogenesis  starts  from  the  fetal  life,  and  its  natural 
course consists of interrelations between traditional risk fac-
tors and inflammatory, immune, and endothelial biomarkers. 
Some  studies  have  suggested  a  role  for  genetic  polymor-
phisms  associated  with  inflammation  and  atherosclerosis 
[75,  76]  but  not  confirmed  by  some  others  [77].  Because  
of considerable ethnic differences in the role of genetic in 
atherosclerosis  [78],  large  multi-centric  studies  should  be 
conducted in this regard. 
  As lifestyle modification trials have been successful  in 
decreasing endothelial dysfunction and the level of markers 
of inflammation among children and adolescents, it is sug-
gested that in addition to expanding pharmacological thera-
pies considered for secondary prevention of atherosclerotic 
diseases  aiming  to  control  the  inflammatory  process,  the 
importance of primordial/primary prevention of atheroscle-
rosis  [79,  80]  should  be  underscored.  Future  studies  are 
needed to find out more details about the role of inflamma-
tion in young ages, notably children and adolescents in order 
to  improve  strategies  for  prediction,  prevention  and  treat-
ment of atherosclerotic events.  
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